Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Post-Mkt 10-15 16:53:37 EDT

0.2405

-0.0151

-5.91%

盘后0.2320

-0.0085-3.53%

16:12 EDT

High0.2729	Low0.2358	Vol1.34M
Open0.2520	D1 Closing0.2556	Amplitude14.51%
Mkt Cap22.10M	Tradable Cap15.33M	Total Shares91.88M
T/O337.58K	T/O Rate2.10%	Tradable Shares63.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":0.2405,"timestamp":1792094400000,"preClose":0.2556,"halted":0,"volume":1337016,"hourTrading":{"tag":"盘后","latestPrice":0.232,"preClose":0.2405,"latestTime":"16:12 EDT","volume":8401,"amount":2026.6846272599998,"timestamp":1792095158401,"change":-0.0085,"changeRate":-0.035343,"amplitude":0.053222},"delay":0,"changeRate":-0.05907668231611895,"floatShares":63733600,"shares":91879177,"eps":-0.482831,"marketStatus":"Post-Mkt","change":-0.0151,"latestTime":"10-15 16:53:37 EDT","open":0.252,"high":0.2729,"low":0.2358,"amount":337581,"amplitude":0.145149,"askPrice":0.27,"askSize":6,"bidPrice":0.2283,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.482831,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792108800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":0.2556,"preHourTrading":{"tag":"盘前","latestPrice":0.2659,"preClose":0.2556,"latestTime":"09:22 EDT","volume":4851,"amount":1297.68203565,"timestamp":1792070539146,"change":0.0103,"changeRate":0.040297,"amplitude":0.078247},"postHourTrading":{"tag":"盘后","latestPrice":0.232,"preClose":0.2405,"latestTime":"16:12 EDT","volume":8401,"amount":2026.6846272599998,"timestamp":1792095158401,"change":-0.0085,"changeRate":-0.035343,"amplitude":0.053222},"volumeRatio":1.581639},"requestUrl":"/m/hq/s/CNTX","defaultTab":"news","newsList":[{"id":"2666580545","title":"Context Therapeutics Doses First Patient in Phase 1 Trial of CT-202 Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580545?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953536,"startTime":"0","endTime":"0","summary":"Context Therapeutics doses first patient in Phase 1 trial of CT-202 bispecific antibodyContext Therapeutics dosed the first patient in a Phase 1 trial of CT-202, a Nectin-4 x CD3 bispecific antibody f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL60Q128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BQXX3D17.EUR","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014013.SGD","LU0314104364.USD","IE00BQXX3C00.GBP","CNTX","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858037","title":"Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of Ct-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858037?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA56JCFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661096","title":"Context downgraded to Market Perform from Outperform at LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661096?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:10","pubTimestamp":1786057829,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Charles Zhu downgraded Context Therapeutics (CNTX) to Market Perform from Outperform. Published first on TheFly – the ultim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-downgraded-to-market-perform-from-outperform-at-lifesci-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-downgraded-to-market-perform-from-outperform-at-lifesci-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663689","title":"Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663689","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:58","pubTimestamp":1786017486,"startTime":"0","endTime":"0","summary":"Ireland's GH Research Q2 net loss widens on higher R&D costsOverviewIreland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expensesCompany's cash and marketable securities","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","IE00BN0W2V16.EUR","LU0154245756.USD","LU0154245673.USD","PSIL","IE00BN0W2T93.GBP","BK4532","LU0823416689.USD","LU0320765992.SGD","LU0889565916.HKD","JAZZ","BK4539","GHRS","BK4139","BK4533","CNTX","BK4007","LU0109394709.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657028705","title":"BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2657028705","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657028705?lang=en_us&edition=fundamental","pubTime":"2026-08-06 14:01","pubTimestamp":1785996076,"startTime":"0","endTime":"0","summary":"BillionToOne stock fell after hours after reporting second-quarter financial results.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/08/60981612/billiontoone-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CNTX","PAVS","BK4007","BK4196","BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657718225","title":"Context Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657718225","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657718225?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:44","pubTimestamp":1785966269,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryContext Therapeutics IncCNTX.OQreported a quarterly adjusted loss of 15 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N4423N3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657576328","title":"Context Therapeutics Q2 FY26 Net Loss Widens 65% to $14.56 Million Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2657576328","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657576328?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:01","pubTimestamp":1785963704,"startTime":"0","endTime":"0","summary":"Context Therapeutics Q2 FY26 net loss widens 65% to $14.56 million year over yearContext Therapeutics posted a net loss of $14.56 million for Q2 2026, widening 65% from a year earlier.Operating loss w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL3T1wNH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520143","title":"Context Therapeutics Inc. Q2 Net Income USD -14.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520143?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:14","pubTimestamp":1785960851,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXZQFJZN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520124","title":"Context Therapeutics Inc. Q2 Basic EPS USD -0.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520124?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:14","pubTimestamp":1785960851,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXZQFJZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657122520","title":"Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2657122520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657122520?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:14","pubTimestamp":1785960851,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUABGX4YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391564","title":"Context Therapeutics Receives Nasdaq Minimum Bid Price Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391564","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391564?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:31","pubTimestamp":1785529894,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) has issued an announcement. On July 29, 2026, Context Therapeutics Inc. received a notification from Nasdaq that i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","NQmain","LCLG","BK4539","BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399956","title":"Context Therapeutics Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399956","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399956?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:10","pubTimestamp":1785528605,"startTime":"0","endTime":"0","summary":"Context Therapeutics gets Nasdaq notice for failing $1 minimum bid price ruleContext Therapeutics received a Nasdaq notice for failing to meet the $1 minimum bid price requirement for 30 consecutive b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL7hWcZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656615399","title":"Context Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656615399","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656615399?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:07","pubTimestamp":1785528439,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc <CNTX.OQ> expected to post a loss of9cents a share - Earnings PreviewContext Therapeutics IncCNTX.OQCNTX.Ois expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X32Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650763132","title":"Context Therapeutics Grants New Hire Stock Options for 146,000 Shares at $0.7 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2650763132","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650763132?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713924,"startTime":"0","endTime":"0","summary":"Context Therapeutics grants new hire stock options for 146,000 shares at $0.7 eachContext Therapeutics granted a non-qualified stock option for 146,000 shares to a new employee, issued as an inducemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL5sQ5qf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","BK4007","LU0314104364.USD","IE00BN0W2W23.USD","CNTX","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BCDF","SG9999014005.SGD","LU2095319765.USD","BK4585","SG9999014013.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650375137","title":"Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650375137","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650375137?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:05","pubTimestamp":1783713900,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, July  10, 2026  (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/10/3325745/0/en/Context-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","LCLG","BK4139","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650750669","title":"Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2650750669","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650750669?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614726,"startTime":"0","endTime":"0","summary":"Context Therapeutics, Inc. ($CNTX) announced an update on their ongoing clinical study. Context Therapeutics Inc. is launching a Phase 1a/1b trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-first-in-human-ct-202-trial-setting-up-a-new-nectin-4-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-first-in-human-ct-202-trial-setting-up-a-new-nectin-4-oncology-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","CNTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679194","title":"Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679194?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:07","pubTimestamp":1783368453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nFWN4380SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360874","title":"Context Therapeutics Shareholders Approve Increase in Authorized Common Shares to 300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360874","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360874?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:08","pubTimestamp":1782504522,"startTime":"0","endTime":"0","summary":"Context Therapeutics shareholders approve increase in authorized common shares to 300 millionContext Therapeutics held its annual shareholder meeting on June 24, 2026.Shareholders backed an amendment ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL72M8XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635200","title":"Context Therapeutics selloff brings buying opportunity, says JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643635200?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:35","pubTimestamp":1781544949,"startTime":"0","endTime":"0","summary":"JonesResearch views today’s selloff in shares of Context Therapeutics (CNTX) as a buying opportunity. Context’s Phase I study update of CTIM-76 in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-selloff-brings-buying-opportunity-says-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-selloff-brings-buying-opportunity-says-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ","CNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643220743","title":"Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643220743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643220743?lang=en_us&edition=fundamental","pubTime":"2026-06-16 00:50","pubTimestamp":1781542219,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyadic International (DYAI) and Context Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyadic-international-dyai-and-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyadic-international-dyai-and-context-therapeutics-cntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","DYAI","BK4139","XLV","BK4007","LU0128526141.USD","BK4588","BK4581","CNTX","XBI","LABU","HCSG","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1823},{"period":"1month","weight":-0.2718},{"period":"3month","weight":-0.5841},{"period":"6month","weight":-0.8948},{"period":"1year","weight":-0.8148},{"period":"ytd","weight":-0.8261}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0115},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.0837},{"period":"1year","weight":0.1621},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.188281},{"month":2,"riseRate":0.2,"avgChangeRate":-0.080088},{"month":3,"riseRate":0.6,"avgChangeRate":-0.010229},{"month":4,"riseRate":0.4,"avgChangeRate":-0.001309},{"month":5,"riseRate":0.8,"avgChangeRate":0.277604},{"month":6,"riseRate":0.6,"avgChangeRate":0.025564},{"month":7,"riseRate":0.6,"avgChangeRate":-0.029484},{"month":8,"riseRate":0.6,"avgChangeRate":-0.023714},{"month":9,"riseRate":0.4,"avgChangeRate":-0.045768},{"month":10,"riseRate":0.6,"avgChangeRate":-0.014933},{"month":11,"riseRate":0.6,"avgChangeRate":-0.036732},{"month":12,"riseRate":0.4,"avgChangeRate":-0.161685}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}